This means that the negotiations to find a partner for outside of Japan are far more complicated because they involve joint parties.
If, as DS states on its website, it "aims for the realization of the Global Pharma Innovator in 2015" and they clearly have a reasonable salesforce outside of Japan, then this could be the wildcard...
...we will see just how interested Glaxo or others are to strike a big deal.
Alternatively, in absence of a suitable deal, will Biota be able to negotiate a fair market deal if DS take the ROW manufacture, sales and marketing?
I would say that there are many possible outcomes, from Director buyback, to Biota being swallowed up by a GSK or DS, through to a strong ROW deal with either an external partner or DS.
If it's a takeover (or Director buyback), then has the current SP volatility anything to do with this?
How many shares need to be purchased by a party before the transaction must be disclosed?
What % of Biota is owned by Directors?
BTA Price at posting:
$2.03 Sentiment: LT Buy Disclosure: Held
